Abstract
More than two decades have been spent to develop many families of synthetic matrix metalloproteinases inhibitors (MMPI) as therapeutical agents for serious pathologies. Unfortunately, clinical trials conducted on broad-spectrum inhibitors have yielded disappointing results, especially in the cancer pathology area. Despite these outcomes, some small synthetic MMPI are in advanced trials or launched in clinical ones for cancer, arthritis, periodontal diseases. Today many groups are developing intensive efforts to find new classes of inhibitors characterized by improved potency and, above all, high selectivity against the specific MMP involved in each targeted pathology. The new challenges include the development of new MMPI bearing more effective ZBGs and the development of new allosteric non-zinc binding inhibitors, devoid of ZBGs. An analysis of more recent results in this field reported on journals and patents will be developed, to consider some of the more interesting new highly selective synthetic MMPI, their SARs, the new theoretical approaches used for modelling and the results of their biological evaluations.
Keywords: Matrix metalloproteinase inhibitors, zinc binding groups, allosteric MMP inhibitors, selective MMP inhibitors
Current Pharmaceutical Design
Title: Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors
Volume: 13 Issue: 20
Author(s): Elisa Nuti, Tiziano Tuccinardi and Armando Rossello
Affiliation:
Keywords: Matrix metalloproteinase inhibitors, zinc binding groups, allosteric MMP inhibitors, selective MMP inhibitors
Abstract: More than two decades have been spent to develop many families of synthetic matrix metalloproteinases inhibitors (MMPI) as therapeutical agents for serious pathologies. Unfortunately, clinical trials conducted on broad-spectrum inhibitors have yielded disappointing results, especially in the cancer pathology area. Despite these outcomes, some small synthetic MMPI are in advanced trials or launched in clinical ones for cancer, arthritis, periodontal diseases. Today many groups are developing intensive efforts to find new classes of inhibitors characterized by improved potency and, above all, high selectivity against the specific MMP involved in each targeted pathology. The new challenges include the development of new MMPI bearing more effective ZBGs and the development of new allosteric non-zinc binding inhibitors, devoid of ZBGs. An analysis of more recent results in this field reported on journals and patents will be developed, to consider some of the more interesting new highly selective synthetic MMPI, their SARs, the new theoretical approaches used for modelling and the results of their biological evaluations.
Export Options
About this article
Cite this article as:
Elisa Nuti , Tiziano Tuccinardi and Armando Rossello , Matrix Metalloproteinase Inhibitors: New Challenges in the Era of Post Broad-Spectrum Inhibitors, Current Pharmaceutical Design 2007; 13 (20) . https://dx.doi.org/10.2174/138161207781039706
DOI https://dx.doi.org/10.2174/138161207781039706 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Oxidative Stress and Antioxidant Potential of One Hundred Medicinal Plants
Current Topics in Medicinal Chemistry Gene Therapy for Dentin Regeneration with Bone Morphogenetic Proteins
Current Gene Therapy Safety of Inhaled Fluticasone Propionate Therapy for Pediatric Asthma - A Systematic Review
Current Drug Safety Structural Heterogeneity and Multifunctionality of Lactoferrin
Current Protein & Peptide Science Intracellular Signaling Triggered by Formyl-Peptide Receptors in Nonphagocytic Cells
Current Signal Transduction Therapy Current Pharmacological Approaches to Prevent and Treat Post- Menopausal Osteoporosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Natural Bioactive Compounds Loaded Eggshell Membrane from Waste Food Industry: Preparation and Characterization
Current Nutraceuticals Design and Evaluation of Sustained Release of Ornidazole by Dental Inserts
Current Drug Metabolism Orofacial Pain and Mastication in Dementia
Current Alzheimer Research Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Current Patents on Osteoinductive Molecules for Bone Tissue Engineering
Recent Patents on Biomedical Engineering (Discontinued) Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications
Current Neuropharmacology Current Knowledge and Perspectives for the Use of Platelet-Rich Plasma (PRP) and Platelet-Rich Fibrin (PRF) in Oral and Maxillofacial Surgery Part 1: Periodontal and Dentoalveolar Surgery
Current Pharmaceutical Biotechnology Promising Alternative Therapeutics for Oral Candidiasis
Current Medicinal Chemistry Sepsis Pathophysiology and Anesthetic Consideration
Cardiovascular & Hematological Disorders-Drug Targets Role of MicroRNA 21 in Mesenchymal Stem Cell (MSC) Differentiation: A Powerful Biomarker in MSCs Derived Cells
Current Pharmaceutical Biotechnology Preface
Current Pharmaceutical Biotechnology Optimal antibiotic dosage for chronic kidney disease patient: a pharmacological manual for oral clinicians
Recent Patents on Anti-Infective Drug Discovery Zeolitic Imidazolate Frameworks (ZIF-8) for Biomedical Applications: A Review
Current Medicinal Chemistry Yoga can Alter the Autonomic Neural Activity: A Critical Analysis
Current Traditional Medicine